Prasad Kulkarni joins Callam Davidson of The Lancet to discuss the safety and immunogenicity of a bivalent conjugate vaccine against typhoid and paratyphoid, following the publication of a phase 1 trial. Read the full article: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00249-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_lancet Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://youtube.com/thelancettv
